A study on the effectiveness of the COVID-19 vaccine, which was barred from inclusion in a federal weekly report, has been published in the peer-reviewed journal JAMA Network Open. Conducted by researchers from the CDC and various states, the study assessed the 2025-26 vaccine’s effectiveness among adults aged 18 and older without weakened immune systems during the fall and winter of 2025. The findings revealed that the updated vaccines reduced the risk of hospitalization from COVID-19 by 55% and related emergency visits by 50% compared to unvaccinated individuals. However, the study’s authors noted that it did not consider prior COVID-19 infections or vaccinations, which could influence immunity levels. This study had initially been intended for publication in the CDC’s Morbidity and Mortality Weekly Report, but faced scrutiny regarding its methodology and was delayed.
Why It Matters
This study is significant as it provides empirical data on the effectiveness of COVID-19 vaccines, contributing to the ongoing discussion about vaccination strategies. The study utilized a test-negative design, a recognized method in epidemiology to evaluate vaccine efficacy, which has been employed in similar research for years. The CDC’s decision to initially block the study from publication raises concerns about transparency in public health communications, especially amidst ongoing debates about vaccine safety and efficacy. Understanding the effectiveness of vaccines is crucial for informing public health policies and encouraging vaccination uptake to combat COVID-19 effectively.
Want More Context? 🔎
